Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Remain Fit and Sound with These Exercise Fundamentals - 2Old age isn’t a modern phenomenon – many people lived long enough to grow old in the olden days, too
- 3When faith comes under fire: How Iran’s repression of religious minorities has increased
- 4Gartex Texprocess India to showcase innovations across textile ecosystem
- 5A Gustav Klimt painting is now the most expensive piece of modern art sold at auction. The fascinating history behind the $236 million 'Portrait of Elisabeth Lederer.'
- Eurasian cargo hub expands to capture Europe-Asia freight flows
- Must-Have Wellness Gear: What to Purchase for Successful Exercises
- Activists Took BMW and Mercedes to Court Over Gas Cars. It Didn’t Stick
- Emergent Cold LatAm opens state-of-the-art cold storage hub in Guadalajara
- Apollo vs. Artemis: What to know about NASA's return to the moon
- Everyone knows F1 is for the girls. I wandered into the Las Vegas desert to find out why.
- Flu surges across U.S. as doctor visits reach highest level since 1997
- Flash flooding causes highways to close to and from Eilat
- The cheap health insurance promoted by Trump officials has this catch
